Pasithea Therapeutics Announces An Independent Safety Review Committee Completes Safety Review Of Data From First Dose Cohort In Phase 1 Trial Of PAS-004
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics announced that an independent safety review committee has completed a safety review of data from the first dose cohort in the Phase 1 trial of PAS-004.
June 13, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pasithea Therapeutics' independent safety review committee has completed a safety review of data from the first dose cohort in the Phase 1 trial of PAS-004, indicating progress in their clinical trials.
The completion of a safety review in a Phase 1 trial is a positive development, suggesting that the trial is progressing without major safety concerns. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100